Dapsone

Last updated
Dapsone
Dapsone.svg
Dapsone3d.png
Clinical data
Trade names Aczone, others
AHFS/Drugs.com Monograph
MedlinePlus a682128
License data
Routes of
administration 		By mouth, topical
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 70 to 80%
Protein binding 70 to 90%
Metabolism Liver (mostly CYP2E1-mediated)
Elimination half-life 20 to 30 hours
Excretion Kidney
Identifiers
  • 4-[(4-aminobenzene)sulfonyl]aniline
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.001.136 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C12H12N2O2S
Molar mass 248.30 g·mol−1
3D model (JSmol)
Melting point 175 to 176 °C (347 to 349 °F)
  • O=S(=O)(c1ccc(N)cc1)c2ccc(N)cc2
  • InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2 Yes check.svgY
  • Key:MQJKPEGWNLWLTK-UHFFFAOYSA-N Yes check.svgY
   (verify)

Dapsone, also known as 4,4'-sulfonyldianiline (SDA) or diaminodiphenyl sulfone (DDS), [1] is an antibiotic commonly used in combination with rifampicin and clofazimine for the treatment of leprosy. [2] It is a second-line medication for the treatment and prevention of pneumocystis pneumonia and for the prevention of toxoplasmosis in those who have poor immune function. [2] Additionally, it has been used for acne, dermatitis herpetiformis, and various other skin conditions. [3] Dapsone is available both topically and by mouth. [4]

Contents

Severe side effects may include a decrease in blood cells, red blood cell breakdown especially in those with glucose-6-phosphate dehydrogenase deficiency (G-6-PD), or hypersensitivity. [2] Common side effects include nausea and loss of appetite. [4] Other side effects include liver inflammation, methemoglobinemia, [5] and a number of types of skin rashes. [2] While the safety of use during pregnancy is not entirely clear some physicians recommend that it be continued in those with leprosy. [2] It is of the sulfone class. [2]

Dapsone was first studied as an antibiotic in 1937. [3] Its use for leprosy began in 1945. [3] It is on the World Health Organization's List of Essential Medicines. [6] The form, which is taken by mouth, is available as a generic drug and not very expensive. [2] [7]

Medical uses

Infections

Dapsone is commonly used in combination with rifampicin and clofazimine for the treatment of leprosy. [2] It is also used to both treat and prevent pneumocystis pneumonia (PCP). [2] [8] It is also used for toxoplasmosis in people unable to tolerate trimethoprim with sulfamethoxazole. [8]

Dapsone by mouth was one of the first medications used to treat moderate to severe acne vulgaris, and is still occasionally prescribed for the treatment of severe cases. [9] [10] A topical form of dapsone is also effective with potentially less side effects. [11]

It is unclear if the combination with pyrimethamine is useful in the prevention of malaria. [12]

Autoimmune disease

Other

Dermatitis herpetiformis in combination with a gluten-free diet. [2]

Dapsone may be used to treat brown recluse spider bites that become necrotic. [18]

Dapsone is the recommended treatment for erythema elevatum diutinum, as a review found that using oral dapsone alone was effective in 80% of early cases of the disease. However, dapsone can potentially cause severe side effects, meaning that sometimes steroids or other antibiotics should be used instead, although these alternative treatments are much less effective. [19]

An August 2015 review notes that dapsone is reported to be effective against generalized granuloma annulare. [20]

Dapsone has been used as a monomer in the design of dye adsorbent polymers. [21]

Contraindications and precautions

People with porphyria, anemia, cardiac disease, lung disease, HIV infection, G6PD deficiency, and liver impairment are at higher risks of adverse effects when using dapsone. [8]

Adverse effects

Hypersensitivity reactions occur in 1.4% of persons treated with dapsone, and can be fatal in medical settings with low resources. [22] [23] It is a form of severe cutaneous adverse reactions (SCARs) in which a SCARs disorder, primarily the DRESS syndrome or a DRESS syndrome-like reaction occurs. [24] [25]

Blood

Hemolysis is the most prominent side-effect, occurring in about 20 % of patients treated with dapsone, [26] although it is dose-related. It may lead to hemolytic anemia and methemoglobinemia. [27] The side-effect is more common and severe in those with glucose-6-phosphate dehydrogenase deficiency, leading to the dapsone-containing antimalarial combination Lapdap being withdrawn from clinical use. [28] [29] A case of hemolysis in a neonate from dapsone in breast milk has been reported. [30] Agranulocytosis occurs rarely when dapsone is used alone but more frequently in combination regimens for malaria prophylaxis. [31] Abnormalities in white blood cell formation, including aplastic anemia, are rare, yet are the cause of the majority of deaths attributable to dapsone therapy. [32] [33] [34]

Methemoglobinemia occurs in about 15 % of patients treated with long-term dapsone at standard doses (100 mg/day). Only special multi-wavelength oximeters (CO-oximeters) can detect methemoglobinemia directly. When there is a "saturation gap" between a low ordinary pulse oximeter reading and a high arterial blood gas analysis result, methemoglobinemia may be suspected. [35]

Liver

Toxic hepatitis and cholestatic jaundice have been reported by the manufacturer. These toxic reactions may also occur as part of the dapsone hypersensitivity syndrome (a form of SCARs-see above) or dapsone syndrome (see below). [24] Dapsone is metabolized by the Cytochrome P450 system, specifically isozymes CYP2D6, CYP2B6, CYP3A4, and CYP2C19. [36] Dapsone metabolites produced by the cytochrome P450 2C19 isozyme are associated with the methemoglobinemia side effect of the drug.[ citation needed ]

Skin

When used topically, dapsone can cause mild skin irritation, redness, dry skin, burning, and itching. When used together with benzoyl peroxide products, temporary yellow or orange skin discolorations can occur. [37]

Dapsone hypersensitivity syndrome

Hypersensitivity reactions occur in some patients. This reaction may be more frequent in patients receiving multiple-drug therapy. [38] [39] [40]

The reaction always involves a rash, may also include fever, jaundice, and eosinophilia, and is likely to be one manifestation of the SCARs reaction viz., the DRESS syndrome (see above). [24] [41] [42] [43] [44] [45] In general, these symptoms will occur within the first six weeks of therapy or not at all, and may be ameliorated by corticosteroid therapy. [8]

Other adverse effects

Other adverse effects include nausea, headache, and rash (which are common), and insomnia, psychosis, and peripheral neuropathy. Effects on the lung occur rarely and may be serious, though are generally reversible. [46]

Mechanism of action

As an antibacterial, dapsone inhibits bacterial synthesis of dihydrofolic acid, via competition with para-aminobenzoate for the active site of dihydropteroate synthase, thereby inhibiting nucleic acid synthesis. [47] Though structurally distinct from dapsone, the sulfonamide group of antibacterial drugs also work in this way.[ citation needed ]

As an anti-inflammatory, dapsone inhibits the myeloperoxidase-H2O2-halide-mediated cytotoxic system in polymorphonucleocytes. [48] As part of the respiratory burst that neutrophils use to kill bacteria, myeloperoxidase converts hydrogen peroxide (H
2O
2) into hypochlorous acid (HOCl). HOCl is the most potent oxidant generated by neutrophils, and can cause significant tissue damage during inflammation. Dapsone arrests myeloperoxidase in an inactive intermediate form, reversibly inhibiting the enzyme. This prevents accumulation of hypochlorous acid, and reduces tissue damage during inflammation. [49] [50] [51] [52] [53] Myeloperoxidase inhibition has also been suggested as a neuron-sparing mechanism for reducing inflammation in neurodegenerative diseases such as Alzheimer's disease and stroke. [54]

Dapsone's anti-inflammatory and immunomodulatory effects [55] are thought to be its mechanism of action in treating dermatitis herpetiformis. [56]

Dapsone is an odorless white to creamy-white crystalline powder with a slightly bitter taste.[ citation needed ]

History

Discovery

Synthesis of dapsone from 4-nitrochlorobenzene by E. Fromm and J. Wittmann, 1908 Dapsone synthesis 2.svg
Synthesis of dapsone from 4-nitrochlorobenzene by E. Fromm and J. Wittmann, 1908

In the early 20th century, the German chemist Paul Ehrlich was developing theories of selective toxicity based largely on the ability of certain dyes to kill microbes. Gerhard Domagk, who would later win a Nobel Prize for his efforts, made a major breakthrough in 1932 with the discovery of the antibacterial prontosil red (sulfonamidochrysoidine). Further investigation into the involved chemicals opened the way to sulfa drug and sulfone therapy, first with the discovery of sulfanilamide, the active agent of prontosil, by Daniel Bovet and his team at Pasteur Institute (1935), [58] then with that of dapsone independently by Ernest Fourneau [59] in France and Gladwin Buttle [60] in the United Kingdom. [61]

Proposed use in antimalarial drugs

The spread of drug-resistant malaria in Africa has encouraged the development of new, low-cost antimalarial drugs. Plasmodium falciparum , one of the Plasmodium species that causes malaria, has developed resistance both to chloroquine and sulfadoxine/pyrimethamine, two of the most common treatments for malaria. Artemisinin, another antimalarial drug, had been developed in the 1980s but was too expensive for large-scale use. This led GlaxoSmithKline to develop Lapdap, a combination drug consisting of chlorproguanil and dapsone. Lapdap was licensed in the United Kingdom starting in October 2003. [29]

One advantage of Lapdap was that chlorproguanil and dapsone are both low-cost drugs. Another was that by virtue of being a combination drug, it was less likely to cause drug resistance. However, because dapsone causes hemolytic anemia in patients with G6PD deficiency, and because G6PD deficiency affects 10-25% of the population of sub-Saharan Africa, it was discovered that Lapdap is not safe for use in Africa. It was available in many African countries for four years before GlaxoSmithKline took it off the market in February 2008. [29]

Dapsone gel

Dapsone had been reported in a few cases to effectively treat acne, but the risk of hemolytic anemia kept it from being widely used for this purpose. For many years scientists attempted to develop a topical formulation of dapsone that would be as effective against acne as oral dapsone, but without the hemolysis side effect. This was difficult to accomplish because dapsone is highly insoluble in aqueous solvents. In the early 2000s QLT USA developed Aczone, a 5% dapsone gel that was shown to be effective against acne without causing clinically significant declines in hemoglobin levels, even in subjects with G6PD deficiency. [62] In February 2016, the FDA approved a 7.5% dapsone gel. This higher strength has the advantage of a once-daily application, versus twice-daily application of the 5% formulation. [63]

Other uses

4,4-Diaminodiphenyl sulfone also finds uses as a curing agent for materials like epoxy resins and imine-based vitrimers, applications include in printed circuit boards, adhesives and coatings. [64] [65] [66] Its use in epoxy systems typically give a resin with a high glass-transition temperature.

See also

Related Research Articles

Stevens–Johnson syndrome (SJS) is a type of severe skin reaction. Together with toxic epidermal necrolysis (TEN) and Stevens–Johnson/toxic epidermal necrolysis (SJS/TEN) overlap, they are considered febrile mucocutaneous drug reactions and probably part of the same spectrum of disease, with SJS being less severe. Erythema multiforme (EM) is generally considered a separate condition. Early symptoms of SJS include fever and flu-like symptoms. A few days later, the skin begins to blister and peel, forming painful raw areas. Mucous membranes, such as the mouth, are also typically involved. Complications include dehydration, sepsis, pneumonia and multiple organ failure.

<span class="mw-page-title-main">Acne</span> Skin condition characterized by pimples

Acne, also known as acne vulgaris, is a long-term skin condition that occurs when dead skin cells and oil from the skin clog hair follicles. Typical features of the condition include blackheads or whiteheads, pimples, oily skin, and possible scarring. It primarily affects skin with a relatively high number of oil glands, including the face, upper part of the chest, and back. The resulting appearance can lead to lack of confidence, anxiety, reduced self-esteem, and, in extreme cases, depression or thoughts of suicide.

<span class="mw-page-title-main">Minocycline</span> Antibiotic medication

Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic medication used to treat a number of bacterial infections such as some occurring in certain forms of pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis. It is taken by mouth or applied to the skin.

<span class="mw-page-title-main">Methemoglobinemia</span> Condition of elevated methemoglobin in the blood

Methemoglobinemia, or methaemoglobinaemia, is a condition of elevated methemoglobin in the blood. Symptoms may include headache, dizziness, shortness of breath, nausea, poor muscle coordination, and blue-colored skin (cyanosis). Complications may include seizures and heart arrhythmias.

<span class="mw-page-title-main">Hypersensitivity</span> Overreaction of the immune system to an antigen

Hypersensitivity is an abnormal physiological condition in which there is an undesirable and adverse immune response to an antigen. It is an abnormality in the immune system that causes immune diseases including allergies and autoimmunity. It is caused by many types of particles and substances from the external environment or from within the body that are recognized by the immune cells as antigens. The immune reactions are usually referred to as an over-reaction of the immune system and they are often damaging and uncomfortable.

<span class="mw-page-title-main">Hives</span> Skin disease characterized by red, raised, and itchy bumps

Hives, also known as urticaria, is a kind of skin rash with red and/or flesh-colored, raised, itchy bumps. Hives may burn or sting. The patches of rash may appear on different body parts, with variable duration from minutes to days, and do not leave any long-lasting skin change. Fewer than 5% of cases last for more than six weeks. The condition frequently recurs.

<span class="mw-page-title-main">Primaquine</span> Pharmaceutical drug

Primaquine is a medication used to treat and prevent malaria and to treat Pneumocystis pneumonia. Specifically it is used for malaria due to Plasmodium vivax and Plasmodium ovale along with other medications and for prevention if other options cannot be used. It is an alternative treatment for Pneumocystis pneumonia together with clindamycin. It is taken by mouth.

<span class="mw-page-title-main">Tazarotene</span> Topical retinoid medication

Tazarotene, sold under the brand name Tazorac, among others, is a third-generation prescription topical retinoid. It is primarily used for the treatment of plaque psoriasis and acne. Tazarotene is also used as a therapeutic for photoaged and photodamaged skin. It is a member of the acetylenic class of retinoids.

<span class="mw-page-title-main">Clofazimine</span> Medication

Clofazimine, sold under the brand name Lamprene, is a medication used together with rifampicin and dapsone to treat leprosy. It is specifically used for multibacillary (MB) leprosy and erythema nodosum leprosum. Evidence is insufficient to support its use in other conditions though a retrospective study found it 95% effective in the treatment of Mycobacterium avium complex (MAC) when administered with a macrolide and ethambutol, as well as the drugs amikacin and clarithromycin. However, in the United States, clofazimine is considered an orphan drug, is unavailable in pharmacies, and its use in the treatment of MAC is overseen by the Food and Drug Administration. It is taken orally.

<span class="mw-page-title-main">Physical urticaria</span> Medical condition

Physical urticaria is a distinct subgroup of urticaria (hives) that are induced by an exogenous physical stimulus rather than occurring spontaneously. There are seven subcategories that are recognized as independent diseases. Physical urticaria is known to be painful, itchy and physically unappealing; it can recur for months to years.

Chlorproguanil/dapsone was a fixed dose antimalarial combination containing chlorproguanil and dapsone, which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.

Acne fulminans is a severe form of the skin disease, acne, which can occur after unsuccessful treatment for another form of acne, acne conglobata. The condition is thought to be an immunologically induced disease in which elevated level of testosterone causes a rise in sebum and population of Cutibacterium acnes bacteria. The increase in the amount of C acnes or related antigens may trigger the immunologic reaction in some individuals and lead to an occurrence of acne fulminans. In addition to testosterone, isotretinoin may also precipitate acne fulminans, possibly related to highly increased levels of C acnes antigens in the patient's immune system. Acne fulminans is a rare disease. Over the past several years, fewer cases of this disease have occurred, possibly because of earlier and better treatment of acne. Approximately 100 patients with acne fulminans have been described.

Drug rash with eosinophilia and systemic symptoms or drug reaction with eosinophilia and systemic symptoms (DRESS), also termed drug-induced hypersensitivity syndrome (DIHS), is a rare reaction to certain medications. It involves primarily a widespread skin rash, fever, swollen lymph nodes, and characteristic blood abnormalities such as an abnormally high level of eosinophils, low number of platelets, and increased number of atypical white blood cells (lymphocytes). However, DRESS is often complicated by potentially life-threatening inflammation of internal organs and the syndrome has about a 10% mortality rate. Treatment consists of stopping the offending medication and providing supportive care. Systemic corticosteroids are commonly used as well but no controlled clinical trials have assessed the efficacy of this treatment.

A leprostatic agent is a drug that interferes with proliferation of the bacterium that causes leprosy.

<span class="mw-page-title-main">Drug eruption</span> Medical condition

In medicine, a drug eruption is an adverse drug reaction of the skin. Most drug-induced cutaneous reactions are mild and disappear when the offending drug is withdrawn. These are called "simple" drug eruptions. However, more serious drug eruptions may be associated with organ injury such as liver or kidney damage and are categorized as "complex". Drugs can also cause hair and nail changes, affect the mucous membranes, or cause itching without outward skin changes.

Acne conglobata is a highly inflammatory disease presenting with comedones, nodules, abscesses, and draining sinus tracts.

<span class="mw-page-title-main">Neonatal acne</span> Medical condition

Neonatal acne, also known as acne neonatorum, is a type of acne that develops in newborns, typically within the first six weeks of life. It presents with open and closed comedones on the cheeks, chin and forehead.

Drug-induced nonautoimmune hemolytic anemia is a uncommon cause of hemolytic anemia. In drug-induced nonautoimmune hemolytic anemia, red blood cells (RBC) are destroyed from various non-immune mechanisms such as direct oxidative stress from certain drugs. This is in contrast to drug-induced autoimmune hemolytic anemia where certain drugs result in the formation of antibodies against RBCs, resulting in hemolysis.

<span class="mw-page-title-main">Promin</span> Chemical compound

Promin, or sodium glucosulfone is a sulfone drug that was investigated for the treatment of malaria, tuberculosis and leprosy. It is broken down in the body to dapsone, which is the therapeutic form.

References

  1. ↑ Lemke TL (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 1142. ISBN   9780781768795. Archived from the original on 2016-03-04.
  2. 1 2 3 4 5 6 7 8 9 10 "Dapsone (Systemic) Monograph for Professionals". The American Society of Health-System Pharmacists. Archived from the original on 2015-01-12. Retrieved January 12, 2015.
  3. 1 2 3 Zhu YI, Stiller MJ (September 2001). "Dapsone and sulfones in dermatology: overview and update". Journal of the American Academy of Dermatology. 45 (3): 420–434. doi:10.1067/mjd.2001.114733. PMID   11511841. S2CID   39874987.
  4. 1 2 Gallant JE (2008). Johns Hopkins HIV Guide 2012. Jones & Bartlett Publishers. p. 193. ISBN   9781449619794. Archived from the original on 2016-03-04.
  5. ↑ Ash-Bernal R, Wise R, Wright SM (September 2004). "Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals". Medicine. 83 (5): 265–273. doi: 10.1097/01.md.0000141096.00377.3f . PMID   15342970. S2CID   40957843.
  6. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. ↑ Greenwood D (2008). Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford University Press. p. 197. ISBN   9780199534845. Archived from the original on 2016-03-04.
  8. 1 2 3 4 Rossi S (2006). Rossi S (ed.). Australian Medicines Handbook. Adelaide. ISBN   0-9757919-2-3.{{cite book}}: CS1 maint: location missing publisher (link)
  9. ↑ Ross CM (October 1961). "The treatment of acne vulgaris with dapsone". The British Journal of Dermatology. 73 (10): 367–370. doi:10.1111/j.1365-2133.1961.tb14398.x. PMID   14494150. S2CID   36293895.
  10. ↑ "Dapsone and Acne Vulgaris". ScienceOfAcne.com. 2012-10-10. Archived from the original on 2012-07-29. Retrieved 2012-08-17.
  11. ↑ Pickert A, Raimer S (June 2009). "An evaluation of dapsone gel 5% in the treatment of acne vulgaris". Expert Opinion on Pharmacotherapy. 10 (9): 1515–1521. doi:10.1517/14656560903002097. PMID   19505219. S2CID   11880942.
  12. ↑ Croft AM (November 2007). "Malaria: prevention in travellers". BMJ Clinical Evidence. 2007. PMC   2943798 . PMID   19450348.
  13. ↑ Chong B, Werth V (2019). "Management of Cutaneous Lupus Erythematosus". In Wallace D (ed.). Dubois' Lupus Erythematosus and Related Syndromes. Edinburgh: Elsevier. pp. 719–726. ISBN   978-0-323-47927-1.
  14. ↑ Weber E, Reynaud Q, Fort R, Durupt S, Cathébras P, Durieu I, Lega JC (September 2017). "Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: A PRISMA-compliant systematic review and meta-analysis of 28 studies". Medicine (Baltimore). 96 (37): e7534. doi:10.1097/MD.0000000000007534. PMC   5604622 . PMID   28906353.
  15. ↑ Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA (October 2018). "Urticaria: A comprehensive review: Treatment of chronic urticaria, special populations, and disease outcomes". J. Am. Acad. Dermatol. 79 (4): 617–633. doi:10.1016/j.jaad.2018.01.023. PMID   30241624. S2CID   52312492.
  16. ↑ Liang SE, Hoffmann R, Peterson E, Soter NA (2019). "Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria". JAMA Dermatol. 155 (1): 90–95. doi:10.1001/jamadermatol.2018.3715. PMC   6439569 . PMID   30476976.
  17. ↑ Rapini RP, Warner NB (2006). "Relapsing polychondritis". Clin. Dermatol. 24 (6): 482–5. doi:10.1016/j.clindermatol.2006.07.018. PMID   17113965.
  18. ↑ Forks TP (2000). "Brown recluse spider bites". The Journal of the American Board of Family Practice. 13 (6): 415–423. doi: 10.3122/15572625-13-6-415 . PMID   11117338.
  19. ↑ Momen SE, Jorizzo J, Al-Niaimi F (December 2014). "Erythema elevatum diutinum: a review of presentation and treatment". Journal of the European Academy of Dermatology and Venereology. 28 (12). John Wiley & Sons: 1594–1602. doi:10.1111/jdv.12566. PMID   25288365. S2CID   30029976.
  20. ↑ Lukács J, Schliemann S, Elsner P (August 2015). "Treatment of generalized granuloma annulare - a systematic review". Journal of the European Academy of Dermatology and Venereology. 29 (8). John Wiley & Sons: 1467–1480. doi:10.1111/jdv.12976. PMID   25651003. S2CID   20884856.
  21. ↑ Khazaei A, Kazem-Rostami M, Zare A, Moosavi-Zare AR, Sadeghpour M, Afkhami A (15 September 2013). "Synthesis, characterization, and application of a triazene-based polysulfone as a dye adsorbent". Journal of Applied Polymer Science. 129 (6): 3439–3446. doi:10.1002/app.39069.
  22. ↑ Lorenz M, Wozel G, Schmitt J (March 2012). "Hypersensitivity reactions to dapsone: a systematic review". Acta Derm. Venereol. 92 (2): 194–9. doi: 10.2340/00015555-1268 . PMID   22307940.
  23. ↑ Zhang FR, Liu H, Irwanto A, et al. (October 2013). "HLA-B*13:01 and the dapsone hypersensitivity syndrome". N Engl J Med. 369 (17): 1620–8. doi: 10.1056/NEJMoa1213096 . PMID   24152261. S2CID   34708642.
  24. 1 2 3 Bocquet H, Bagot M, Roujeau JC (December 1996). "Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS)". Semin Cutan Med Surg. 15 (4): 250–7. doi:10.1016/S1085-5629(96)80038-1. PMID   9069593.
  25. ↑ Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, Jantararoungtong T, Koomdee N, Mahakkanukrauh A, Tassaneeyakul W, Suttisai S, Pratoomwun J, Klaewsongkram J, Rerkpattanapipat T, Sukasem C (December 2017). "Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population". Pharmacogenetics and Genomics. 27 (12): 429–437. doi:10.1097/FPC.0000000000000306. PMID   28885988. S2CID   4283457.
  26. ↑ Puavilai S, Chutha S, Polnikorn N, et al. (July 1984). "Incidence of anemia in leprosy patients treated with dapsone". J Med Assoc Thai. 67 (7): 404–7. PMID   6512448.
  27. ↑ Jopling WH (1983). "Side-effects of antileprosy drugs in common use". Lepr Rev. 54 (4): 261–70. doi: 10.5935/0305-7518.19830032 . PMID   6199637.
  28. ↑ "Antimalarial chlorproguanil-dapsone (LapDap™) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (Dacart™) versus artemether-lumefantrine (Coartem®) and confirmation of findings in a comparative trial of LapDap™ versus Dacart ™" (PDF). World Health Organization. 4 March 2008. QSM/MC/IEA.1. Archived (PDF) from the original on 21 October 2012.
  29. 1 2 3 Luzzatto L (August 2010). "The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics". Lancet. 376 (9742): 739–41. doi:10.1016/S0140-6736(10)60396-0. PMID   20599264. S2CID   34866078.
  30. ↑ Sanders SW, Zone JJ, Foltz RL, Tolman KG, Rollins DE (April 1982). "Hemolytic anemia induced by dapsone transmitted through breast milk". Ann Intern Med. 96 (4): 465–6. doi:10.7326/0003-4819-96-4-465. PMID   7065565.
  31. ↑ Firkin FC, Mariani AF (1977). "Agranulocytosis due to dapsone". Med. J. Aust. 2 (8): 247–51. doi:10.5694/j.1326-5377.1977.tb117649.x. PMID   909500. S2CID   34641425.
  32. ↑ Foucauld J, Uphouse W, Berenberg J (1985). "Dapsone and aplastic anemia". Ann. Intern. Med. 102 (1): 139. doi:10.7326/0003-4819-102-1-139_2. PMID   3966740.
  33. ↑ Meyerson MA, Cohen PR (1994). "Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus". Mayo Clin. Proc. 69 (12): 1159–62. doi:10.1016/s0025-6196(12)65768-1. PMID   7967777.
  34. ↑ Björkman A, Phillips-Howard PA (1991). "Adverse reactions to sulfa drugs: implications for malaria chemotherapy". Bull. World Health Organ. 69 (3): 297–304. PMC   2393107 . PMID   1893504.
  35. ↑ Singh S, Sethi N, Pandith S, Ramesh GS (January 2014). "Dapsone-induced methemoglobinemia: "Saturation gap"-The key to diagnosis". Journal of Anaesthesiology Clinical Pharmacology. 30 (1): 86–88. doi: 10.4103/0970-9185.125710 . PMC   3927300 . PMID   24574600.
  36. ↑ Ganesan S, Sahu R, Walker LA, Tekwani BL (April 2010). "Cytochrome P450-dependent toxicity of dapsone in human erythrocytes". Journal of Applied Toxicology. 30 (3): 271–275. doi:10.1002/jat.1493. PMID   19998329. S2CID   33330708.
  37. ↑ "Aczone (Dapsone) Package insert" (PDF). Irvine CA: Allergan Inc. 2016 – via U.S. Food and Drug Administration.
  38. ↑ Richardus JH, Smith TC (1989). "Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy". Lepr Rev. 60 (4): 267–73. doi: 10.5935/0305-7518.19890033 . PMID   2491425.
  39. ↑ Kumar RH, Kumar MV, Thappa DM (1998). "Dapsone syndrome—a five year retrospective analysis". Indian J Lepr. 70 (3): 271–6. PMID   9801899.
  40. ↑ Rao PN, Lakshmi TS (2001). "Increase in the incidence of dapsone hypersensitivity syndrome—an appraisal". Lepr Rev. 72 (1): 57–62. doi: 10.5935/0305-7518.20010009 . PMID   11355519.
  41. ↑ Joseph MS (1985). "Hypersensitivity reaction to dapsone. Four case reports". Lepr Rev. 56 (4): 315–20. doi: 10.5935/0305-7518.19850034 . PMID   4079634.
  42. ↑ Jamrozik K (1986). "Dapsone syndrome occurring in two brothers". Lepr Rev. 57 (1): 57–62. doi: 10.5935/0305-7518.19860010 . PMID   3702581.
  43. ↑ Hortaleza AR, Salta-Ramos NG, Barcelona-Tan J, Abad-Venida L (1995). "Dapsone syndrome in a Filipino man". Lepr Rev. 66 (4): 307–13. doi: 10.5935/0305-7518.19950034 . PMID   8637384.
  44. ↑ Tomecki KJ, Catalano CJ (1981). "Dapsone hypersensitivity. The sulfone syndrome revisited". Arch Dermatol. 117 (1): 38–9. doi:10.1001/archderm.1981.01650010044023. PMID   6450569.
  45. ↑ Kromann NP, Vilhelmsen R, Stahl D (1982). "The dapsone syndrome". Arch Dermatol. 118 (7): 531–2. doi:10.1001/archderm.1982.01650190085028. PMID   7092282.
  46. ↑ Jaffuel D, Lebel B, Hillaire-Buys D, Pene J, Godard P, Michel FB, Blayac JP, Bousquet J, Demolyi P (1998). "Eosinophilic pneumonia induced by dapsone". BMJ. 317 (7152): 181. doi:10.1136/bmj.317.7152.181. PMC   28611 . PMID   9665900.
  47. ↑ "Mechanisms of Action of Dapsone in Dermatological Diseases". Dapsone: Clinical Uses in Various Cutaneous Diseases. Medscape Today. Archived from the original on May 17, 2011.
  48. ↑ Galijasevic S (January 2019). "The development of myeloperoxidase inhibitors". Bioorganic & Medicinal Chemistry Letters. 29 (1): 1–7. doi:10.1016/j.bmcl.2018.11.031. PMID   30466896. S2CID   53721156.
  49. ↑ Bozeman PM, Learn DB, Thomas EL (January 1990). "Assay of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase". Journal of Immunological Methods. 126 (1): 125–133. doi:10.1016/0022-1759(90)90020-v. PMID   2154520.
  50. ↑ Bozeman PM, Learn DB, Thomas EL (August 1992). "Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone". Biochemical Pharmacology. 44 (3): 553–563. doi:10.1016/0006-2952(92)90449-s. PMID   1324677.
  51. ↑ Stendahl O, Molin L, Lindroth M (March 1983). "Granulocyte-mediated release of histamine from mast cells. Effect of myeloperoxidase and its inhibition by antiinflammatory sulfone compounds". International Archives of Allergy and Applied Immunology. 70 (3): 277–284. doi:10.1159/000233335. PMID   6186607.
  52. ↑ Kettle AJ, Gedye CA, Winterbourn CC (May 1993). "Superoxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase". Biochemical Pharmacology. 45 (10): 2003–2010. doi:10.1016/0006-2952(93)90010-t. PMID   8390258.
  53. ↑ Kettle AJ, Winterbourn CC (May 1991). "Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs". Biochemical Pharmacology. 41 (10): 1485–1492. doi:10.1016/0006-2952(91)90565-m. PMID   1850278.
  54. ↑ Diaz-Ruiz A, Zavala C, Montes S, Ortiz-Plata A, Salgado-Ceballos H, Orozco-Suarez S, et al. (November 2008). "Antioxidant, antiinflammatory and antiapoptotic effects of dapsone in a model of brain ischemia/reperfusion in rats". Journal of Neuroscience Research. 86 (15): 3410–3419. doi:10.1002/jnr.21775. PMID   18615706. S2CID   5837071.
  55. ↑ Begon E, Chosidow O, Wolkenstein P (December 2004). "[Disulone]". Ann Dermatol Venereol (in French). 131 (12): 1062–73. doi:10.1016/S0151-9638(04)93842-2. PMID   15692440.
  56. ↑ Uetrecht JP (1995). "Myeloperoxidase as a generator of drug free radicals". Biochem. Soc. Symp. 61: 163–70. doi:10.1042/bss0610163. PMID   8660393. S2CID   12471553.
  57. ↑ Derivatives of p-Nitrothiophenols, by E. Fromm and J. Wittmann
    Reports of the German Chemical Society Mai–August 1908 Fromm E, Wittmann J (May 1908). "Derivate desp-Nitrothiophenols". Berichte der Deutschen Chemischen Gesellschaft. 41 (2): 2264–2273. doi:10.1002/cber.190804102131.
  58. ↑ Tréfouël JT, Nitti F, Bovet D (23 November 1935). "Activité du p.aminophénylsulfamide sur l'infection streptococcique expérimentale de la souris et du lapin". Comptes rendus des séances de la Société de biologie et de ses filiales (in French). 120: 756. Archived from the original on 3 January 2017.
  59. ↑ Fourneau E, Tréfouël TJ, Nitti F, Bovet D (1937). "Action antistreptococcique des dérivés sulfurés organiques". Comptes rendus de l'Académie des sciences (in French). 204: 1763. Archived from the original on 2016-02-20.
  60. ↑ Buttle G, Stephenson D, Smith S, Dewing T, Foster G (June 1937). "Treatment of streptococcal infections in mice with 4:4'diamino-dipheni-sulphone". Lancet. 229 (5936): 1331–4. doi:10.1016/S0140-6736(00)75868-5.
  61. ↑ "Leprosy | 14 History of dapsone and dyes". Archived from the original on 2009-02-12. Retrieved 2009-02-24.
  62. ↑ Stotland M, Shalita AR, Kissling RF (June 2009). "Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris". American Journal of Clinical Dermatology. 10 (4): 221–227. doi:10.2165/00128071-200910040-00002. PMID   19489655. S2CID   19485887.
  63. ↑ "Aczone (dapsone) 7.5% Gel Prescribing Information" (PDF). Allergan. February 2016. Retrieved 23 June 2016.
  64. ↑ "ECHA dapsone registration dossier".
  65. ↑ "LAPOX ASH-10". 3 June 2017.
  66. ↑ Schoustra SK, Dijksman JA, Zuilhof H, Smulders MM (November 2020). "Molecular control over vitrimer-like mechanics - tuneable dynamic motifs based on the Hammett equation in polyimine materials". Chemical Science. 12 (1): 293–302. doi:10.1039/d0sc05458e. PMC   8178953 . PMID   34163597.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.